Drug Patents Expiring in 2035

1. List of Absorica Ld drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750711 SUN PHARM Low dose oral pharmaceutical composition of isotretinoin
May, 2035

(12 years from now)

US9700535 SUN PHARM Oral pharmaceutical composition of isotretinoin
Aug, 2035

(12 years from now)

Drugs and Companies using ISOTRETINOIN ingredient

Market Authorisation Date: 05 November, 2019

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

ABSORICA LD family patents

5

United States

3

Mexico

2

Morocco

2

IB

2

Brazil

2

Australia

2

Canada

2

India

2

Russia

2

Japan

2

European Union

1

South Africa

2. List of Accrufer drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9802973 SHIELD TX Crystalline forms of ferric maltol
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10179120 SHIELD TX Dosage regimen of ferric trimaltol
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 25, 2024

Drugs and Companies using FERRIC MALTOL ingredient

NCE-1 date: July, 2023

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage

ACCRUFER family patents

4

Japan

3

United Kingdom

3

China

3

European Union

2

Korea, Republic of

2

Australia

2

Spain

2

United States

2

Canada

1

Brazil

1

Chile

1

Poland

1

Saudi Arabia

1

Israel

1

Mexico

1

Slovenia

1

IB

1

South Africa

1

Singapore

1

EA

3. List of Adhansia Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10292938 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10512612 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10111839 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10292939 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10449159 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10512613 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10500162 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10568841 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10507186 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10688060 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US9974752 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 27, 2022
M Jun 28, 2024

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 February, 2019

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

ADHANSIA XR family patents

14

United States

7

Canada

3

Australia

2

Chile

2

Singapore

2

Japan

1

Hong Kong

1

Korea, Republic of

1

Brazil

1

South Africa

1

Argentina

1

Israel

1

Taiwan, Province of China

1

Mexico

1

EA

1

China

1

European Union

4. List of Adrenalin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295657 PAR STERILE PRODUCTS Epinephrine formulations
Mar, 2035

(12 years from now)

US9119876 PAR STERILE PRODUCTS Epinephrine formulations
Mar, 2035

(12 years from now)

US10130592 PAR STERILE PRODUCTS Epinephrine formulations
Mar, 2035

(12 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 07 December, 2012

Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

How can I launch a generic of ADRENALIN before it's patent expiration?
More Information on Dosage

ADRENALIN family patents

10

United States

1

Korea, Republic of

1

Australia

1

Canada

1

China

1

Japan

1

European Union

5. List of Airduo Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415008

(Pediatric)

TEVA PHARM Dry powder inhaler
Apr, 2035

(12 years from now)

US9066957

(Pediatric)

TEVA PHARM Dry powder inhaler
Apr, 2035

(12 years from now)

US9782550 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(12 years from now)

US9782551 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(12 years from now)

US10918816 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
M Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

10

United States

7

European Union

5

Israel

5

Japan

4

China

4

Australia

4

Spain

3

South Africa

2

Korea, Republic of

2

Brazil

2

Argentina

2

Canada

2

Taiwan, Province of China

2

EA

2

Mexico

1

Hong Kong

6. List of Akynzeo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10676440 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US10961195 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US10233154 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US9951016 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 10 October, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

AKYNZEO family patents

6

United States

1

IB

1

Korea, Republic of

1

Australia

1

Canada

1

Taiwan, Province of China

1

China

1

Japan

1

European Union

7. List of Alecensa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11433076 HOFFMANN-LA ROCHE Preparation containing tetracyclic compound at high dose
Apr, 2035

(12 years from now)

US10350214 HOFFMANN-LA ROCHE Preparation containing tetracyclic compound at high dose
Apr, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 6, 2024

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ALECENSA before it's patent expiration?
More Information on Dosage

ALECENSA family patents

4

United States

4

Japan

2

Korea, Republic of

2

Australia

2

Canada

2

Israel

2

Russia

2

Taiwan, Province of China

2

Singapore

2

China

1

Brazil

1

South Africa

1

Argentina

1

Malaysia

1

Mexico

1

European Union

8. List of Alunbrig drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10385078 TAKEDA PHARMS USA Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Nov, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2022
Orphan Drug Exclusivity (ODE) May 22, 2027
New Indication (I) May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage

ALUNBRIG family patents

6

United States

3

China

2

Korea, Republic of

2

Israel

2

Japan

2

European Union

1

RS

1

Australia

1

Chile

1

Lithuania

1

Ukraine

1

Dominican Republic

1

Spain

1

Mexico

1

Tunisia

1

Slovenia

1

Hungary

1

South Africa

1

Portugal

1

Colombia

1

Peru

1

Singapore

1

Croatia

1

EA

1

Philippines

1

Canada

1

New Zealand

1

Denmark

1

Costa Rica

1

Ecuador

9. List of Amvuttra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 13, 2027

Drugs and Companies using VUTRISIRAN ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

AMVUTTRA family patents

12

United States

3

Singapore

3

Japan

3

European Union

2

Israel

2

China

1

Korea, Republic of

1

EA

1

Canada

1

Mexico

10. List of Aponvie drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 16 September, 2022

Treatment: A method of administering aprepitant for prevention of post-operative nausea and vomiting

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage

APONVIE family patents

14

United States

3

Japan

1

Korea, Republic of

1

China

1

European Union

11. List of Arakoda drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888558 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Dec, 2035

(12 years from now)

US10342791 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Dec, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2023

Drugs and Companies using TAFENOQUINE SUCCINATE ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 08 August, 2018

Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose

Dosage: TABLET;ORAL

More Information on Dosage

ARAKODA family patents

6

United States

2

Australia

1

Hong Kong

1

Canada

1

Singapore

1

China

1

European Union

12. List of Arikayce Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446318 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(12 years from now)

US10751355 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(12 years from now)

US9895385 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(12 years from now)

US10251900 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in non-cystic fibrosis adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

ARIKAYCE KIT family patents

17

United States

3

Spain

3

Japan

3

European Union

2

Korea, Republic of

2

Australia

2

Poland

2

Lithuania

2

Slovenia

2

Portugal

2

Croatia

2

Denmark

1

RS

1

Brazil

1

Mexico

1

Hungary

1

China

1

ME

1

Canada

1

New Zealand

13. List of Aristada drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9452131 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US9526726 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US11406632 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US10238651 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US10813928 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous injection

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA family patents

8

United States

2

Australia

2

Israel

2

Russia

2

China

2

Japan

1

Morocco

1

Brazil

1

Canada

1

New Zealand

1

Mexico

1

European Union

14. List of Aristada Initio Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154552 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(12 years from now)

US10849894 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(12 years from now)

US10688091 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(12 years from now)

US10016415 ALKERMES INC Aripiprazole prodrug compositions
Sep, 2035

(12 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA INITIO KIT family patents

6

United States

4

European Union

3

Japan

3

China

2

RS

2

Poland

2

Lithuania

2

Spain

2

Israel

2

Slovenia

2

Hungary

2

Portugal

2

Russia

2

Croatia

2

Denmark

1

Brazil

1

Australia

1

Cyprus

1

Mexico

1

Turkey

1

Canada

15. List of Armonair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782551 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(12 years from now)

US9782550 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(12 years from now)

US10918816 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

10

United States

7

European Union

5

Israel

5

Japan

4

China

4

Australia

4

Spain

3

South Africa

2

Korea, Republic of

2

Brazil

2

Argentina

2

Canada

2

Taiwan, Province of China

2

EA

2

Mexico

1

Hong Kong

16. List of Axumin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10124079 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(12 years from now)

US10933147 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(12 years from now)

US10716868 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(12 years from now)

US10967077 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(12 years from now)

Drugs and Companies using FLUCICLOVINE F-18 ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

17. List of Bafiertam drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9814692 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(12 years from now)

US9636318 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(12 years from now)

US9814691 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(12 years from now)

US10105336 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(12 years from now)

US9820961 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(12 years from now)

US10098863 BANNER LIFE SCIENCES Fumarate esters
Feb, 2035

(12 years from now)

US9566259 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(12 years from now)

US9636319 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(12 years from now)

US10105337 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(12 years from now)

US9326947 BANNER LIFE SCIENCES Controlled release fumarate esters
Feb, 2035

(12 years from now)

US9820960 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(12 years from now)

US9517209 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(12 years from now)

US10105335 BANNER LIFE SCIENCES Fumarate ester dosage forms
Feb, 2035

(12 years from now)

US9511043 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Feb, 2035

(12 years from now)

US9326965 BANNER LIFE SCIENCES Controlled release fumarate esters
Feb, 2035

(12 years from now)

US10918616 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Jun, 2035

(12 years from now)

US10918617 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions
Aug, 2035

(12 years from now)

US10918615 BANNER LIFE SCIENCES Fumarate esters
Aug, 2035

(12 years from now)

US10945985 BANNER LIFE SCIENCES Fumarate ester dosage forms
Aug, 2035

(12 years from now)

Drugs and Companies using MONOMETHYL FUMARATE ingredient

Market Authorisation Date: 28 April, 2020

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

BAFIERTAM family patents

34

United States

4

Australia

3

European Union

2

Spain

2

Canada

2

Israel

2

Denmark

18. List of Balversa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9902714 JANSSEN BIOTECH Quinoxaline derivatives useful as FGFR kinase modulators
Mar, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

BALVERSA family patents

3

United States

3

European Union

1

Morocco

1

RS

1

Korea, Republic of

1

Australia

1

Chile

1

Poland

1

Lithuania

1

Ukraine

1

Jordan

1

Spain

1

Israel

1

Cyprus

1

Mexico

1

Japan

1

Slovenia

1

Hungary

1

Argentina

1

South Africa

1

Portugal

1

Singapore

1

EA

1

China

1

Croatia

1

Turkey

1

Philippines

1

New Zealand

1

Canada

1

Taiwan, Province of China

1

Denmark

1

Costa Rica

1

Nicaragua

19. List of Biktarvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9708342 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10385067 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
Jun, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 18, 2026
New Chemical Entity Exclusivity (NCE) Feb 7, 2023
New Patient Population (NPP) Jun 18, 2022
M Feb 24, 2024

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 07 February, 2018

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of BIKTARVY before it's patent expiration?
More Information on Dosage

BIKTARVY family patents

5

United States

4

Japan

2

Morocco

2

Australia

2

Moldova, Republic of

2

Mexico

2

EA

2

China

2

Taiwan, Province of China

2

European Union

1

RS

1

Korea, Republic of

1

Brazil

1

Chile

1

Poland

1

Cuba

1

Malaysia

1

Lithuania

1

Ukraine

1

Dominican Republic

1

Uruguay

1

Spain

1

Israel

1

Cyprus

1

Slovenia

1

Hungary

1

Argentina

1

Portugal

1

El Salvador

1

Peru

1

Singapore

1

Croatia

1

Turkey

1

ME

1

Philippines

1

Norway

1

New Zealand

1

Canada

1

Denmark

1

Costa Rica

1

Ecuador

20. List of Brexafemme drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10174074 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(11 years from now)

US10927142 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10370406 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 1, 2026
Generating Antibiotic Incentives Now (GAIN) Jun 1, 2031

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

NCE-1 date: June, 2030

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)

Dosage: TABLET;ORAL

More Information on Dosage

BREXAFEMME family patents

5

United States

2

European Union

1

Slovenia

1

Hong Kong

1

RS

1

Hungary

1

EA

1

Spain

1

Portugal

1

Poland

1

Lithuania

1

Denmark

1

Croatia

1

China

21. List of Bunavail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522188 BDSI Abuse resistant transmucosal drug delivery device
Apr, 2035

(12 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: NA

Dosage: FILM;BUCCAL

How can I launch a generic of BUNAVAIL before it's patent expiration?
More Information on Dosage

BUNAVAIL family patents

8

United States

1

Brazil

1

Australia

1

Canada

1

China

1

Japan

1

European Union

22. List of Calquence drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 21, 2026
New Chemical Entity Exclusivity (NCE) Oct 31, 2022
New Indication (I) Nov 21, 2022

Drugs and Companies using ACALABRUTINIB ingredient

NCE-1 date: October, 2021

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab

Dosage: CAPSULE;ORAL

How can I launch a generic of CALQUENCE before it's patent expiration?
More Information on Dosage

CALQUENCE family patents

12

United States

3

IB

3

Taiwan, Province of China

2

Argentina

1

Korea, Republic of

1

Australia

1

Canada

1

EA

1

China

1

Japan

1

European Union

23. List of Calquence drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily

Dosage: TABLET;ORAL

More Information on Dosage

CALQUENCE family patents

12

United States

3

IB

3

Taiwan, Province of China

2

Argentina

1

Korea, Republic of

1

Australia

1

Canada

1

EA

1

China

1

Japan

1

European Union

24. List of Cinvanti drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 09 November, 2017

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

How can I launch a generic of CINVANTI before it's patent expiration?
More Information on Dosage

CINVANTI family patents

14

United States

3

Japan

1

Korea, Republic of

1

China

1

European Union

25. List of Cyclophosphamide drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662342 EUGIA PHARMA SPECLTS Formulations of cyclophosphamide liquid concentrate
Jun, 2035

(12 years from now)

Drugs and Companies using CYCLOPHOSPHAMIDE ingredient

Market Authorisation Date: 25 August, 2021

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of CYCLOPHOSPHAMIDE before it's patent expiration?
More Information on Dosage

CYCLOPHOSPHAMIDE family patents

5

United States

1

Korea, Republic of

1

Brazil

1

Australia

1

Canada

1

Russia

1

China

1

Japan

1

European Union

26. List of Dayvigo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188652 EISAI INC Compositions and methods for treating insomnia
Oct, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 7, 2025

Drugs and Companies using LEMBOREXANT ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

More Information on Dosage

DAYVIGO family patents

5

United States

2

Singapore

2

Japan

1

China

1

Korea, Republic of

1

Brazil

1

Australia

1

Russia

1

Spain

1

Canada

1

Israel

1

Mexico

1

European Union

27. List of Definity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11395856 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(12 years from now)

US10022460 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583207 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(12 years from now)

Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

DEFINITY family patents

6

United States

2

Hong Kong

2

Australia

2

Israel

2

Taiwan, Province of China

2

Mexico

2

China

2

Japan

1

Korea, Republic of

1

Brazil

1

South Africa

1

Spain

1

Canada

1

EA

1

European Union

28. List of Epidiolex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11096905 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10709671 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11311498 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11357741 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11446258 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11154516 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9949937 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9956186 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10092525 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9956183 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10111840 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10137095 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10603288 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10709674 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9956184 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US9956185 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10849860 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10966939 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US10709673 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Jun, 2035

(12 years from now)

US11065209 GW RES LTD Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(12 years from now)

US11400055 GW RES LTD Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(12 years from now)

US10918608 GW RES LTD Use of cannabidiol in the treatment of epilepsy
Oct, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2023
Orphan Drug Exclusivity (ODE) Jul 31, 2027
New Patient Population (NPP) Jul 31, 2023

Drugs and Companies using CANNABIDIOL ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of focal seizures in patients with dravet syndrome; Use for the treatment of absence seizures in patients with dravet syndrome; Use for the treatment of absence seizures in patients with lennox-gastaut syndrome; Use for the treatment of seizures in patients with lennox-gastaut syndrome; Use for the treatment of seizures in patients with dravet syndrome; Use for the treatment of seizures in patients with tuberous sclerosis complex; Use for the treatment of seizures associated with dravet syndrome; Use for the treatment of seizures associated with lennox-gastaut syndrome; Use in combination with clobazam for the treatment of seizures in patients with dravet syndrome; Use for the treatment of convulsive seizures in patients with lennox gastaut syndrome; Use for the treatment of drop seizures in patients with dravet syndrome; Use in combination with clobazam for the treatment of seizures in patients with lennox gastaut syndrome who have been previously treated with clobazam; Use in combination with clobazam for the treatment of seizures in patients with dravet syndrome who have been previously treated with clobazam; Use for the treatment of atonic seizures in patients with dravet syndrome; Use for the treatment of atonic seizures in patients with lennox-gastaut syndrome; Use for the treatment of drop seizures in patients with lennox-gastaut syndrome; Use in combination with clobazam for treatment of drop seizures in patients with lennox gastaut syndrome; Use for reducing convulsive seizure frequency in patients with lennox gastaut syndrome; Use for reducing convulsive seizure frequency in patients with dravet syndrome; Use in combination with clobazam for treatment of seizures in patients with lennox gastaut syndrome; Use for the treatment of convulsive seizures in patients with dravet syndrome; Use for the treatment of generalized seizures or focal seizures with impairment in patients with tuberous sclerosis complex; Use for reducing seizure frequency in patients with tuberous sclerosis complex

Dosage: SOLUTION;ORAL

How can I launch a generic of EPIDIOLEX before it's patent expiration?
More Information on Dosage

EPIDIOLEX family patents

33

United States

13

Japan

12

Australia

10

United Kingdom

9

Mexico

7

European Union

6

Canada

5

Israel

4

Brazil

4

Spain

3

Poland

2

RS

2

Lithuania

2

Slovenia

2

Hungary

2

Portugal

2

Croatia

2

Denmark

1

Hong Kong

29. List of Ermeza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9345772 MYLAN Liquid levothyroxine formulations
Feb, 2035

(12 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 29 April, 2022

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage

30. List of Eskata drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098910 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(12 years from now)

US9980983 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(12 years from now)

US10493103 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(12 years from now)

US10729720 ACLARIS Peroxide formulations and methods and applicators for using the same
Apr, 2035

(12 years from now)

US9675639 ACLARIS Peroxide formulations and methods and applicators for using the same
Jul, 2035

(12 years from now)

Drugs and Companies using HYDROGEN PEROXIDE ingredient

Market Authorisation Date: 14 December, 2017

Treatment: Treatment of seborrheic keratoses that are raised

Dosage: SOLUTION;TOPICAL

More Information on Dosage

ESKATA family patents

10

United States

1

Korea, Republic of

1

Denmark

1

Brazil

1

Australia

1

Spain

1

Portugal

1

Canada

1

Israel

1

Russia

1

Singapore

1

Mexico

1

China

1

Japan

1

European Union

31. List of Evrysdi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 7, 2027
New Chemical Entity Exclusivity (NCE) Aug 7, 2025
New Patient Population (NPP) May 27, 2025

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: August, 2024

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

EVRYSDI family patents

4

United States

3

European Union

2

Morocco

2

Korea, Republic of

2

Israel

2

Hungary

2

EA

1

RS

1

Brazil

1

Australia

1

Chile

1

Poland

1

Lithuania

1

Ukraine

1

Netherlands

1

Spain

1

Mexico

1

Japan

1

Slovenia

1

South Africa

1

Argentina

1

Portugal

1

Peru

1

Singapore

1

Croatia

1

China

1

Philippines

1

Norway

1

Canada

1

New Zealand

1

Taiwan, Province of China

1

Denmark

1

Costa Rica

32. List of Evzio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone
Mar, 2035

(12 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

33. List of Evzio (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone
Mar, 2035

(12 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

34. List of Exem Foam Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259494 GISKIT Composition and method for medical imaging of body cavities
May, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 7, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 07 November, 2019

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

More Information on Dosage

EXEM FOAM KIT family patents

4

United States

2

Netherlands

1

Denmark

1

Spain

1

Poland

1

European Union

35. List of Exkivity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10227342 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(12 years from now)

US9796712 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 15, 2026
Orphan Drug Exclusivity (ODE) Sep 15, 2028

Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient

NCE-1 date: September, 2025

Market Authorisation Date: 15 September, 2021

Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chemotherapy

Dosage: CAPSULE;ORAL

More Information on Dosage

EXKIVITY family patents

6

United States

4

Japan

3

European Union

2

Morocco

2

Korea, Republic of

2

Australia

2

Chile

2

Israel

2

Georgia

2

Singapore

2

China

2

New Zealand

1

RS

1

Brazil

1

Poland

1

Cuba

1

Lithuania

1

Saudi Arabia

1

Ukraine

1

Spain

1

Cyprus

1

Mexico

1

Tunisia

1

Slovenia

1

Hungary

1

South Africa

1

Portugal

1

Colombia

1

Peru

1

EA

1

ME

1

Croatia

1

Turkey

1

Philippines

1

Canada

1

Denmark

1

Costa Rica

1

Ecuador

36. List of Fetroja drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10004750 SHIONOGI INC Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
Sep, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949982 SHIONOGI INC Preparation containing cephalosporin having a catechol moiety
Sep, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
New Indication (I) Sep 25, 2023
Generating Antibiotic Incentives Now (GAIN) Nov 14, 2029

Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient

NCE-1 date: November, 2028

Market Authorisation Date: 14 November, 2019

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

FETROJA family patents

6

Japan

3

Korea, Republic of

2

United States

2

China

2

European Union

1

Morocco

1

RS

1

Brazil

1

Australia

1

Poland

1

Lithuania

1

Malaysia

1

Spain

1

Mexico

1

Slovenia

1

Hungary

1

Portugal

1

Croatia

1

EA

1

Philippines

1

Canada

1

Taiwan, Province of China

1

Denmark

37. List of Fintepla drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10950331 ZOGENIX INC Control system for control of distribution of medication
Sep, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 25, 2027
New Product (NP) Jun 25, 2023
New Indication (I) Mar 25, 2025
Pediatric Exclusivity (PED) Dec 25, 2027

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution

Dosage: SOLUTION;ORAL

How can I launch a generic of FINTEPLA before it's patent expiration?
More Information on Dosage

FINTEPLA family patents

4

United States

2

Australia

2

New Zealand

2

Israel

2

Japan

2

European Union

1

China

1

IB

1

Korea, Republic of

1

Brazil

1

South Africa

1

Russia

1

Canada

1

Saudi Arabia

1

Singapore

1

Mexico

38. List of Firvanq Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959947 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(12 years from now)

US10959948 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(12 years from now)

US10959949 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(12 years from now)

US10959946 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(12 years from now)

US10688046 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(12 years from now)

US10493028 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(12 years from now)

Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient

Market Authorisation Date: 26 January, 2018

Treatment: Treatment of staphylococcal enterocolitis; Treatment of c. difficile-associated diarrhea

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of FIRVANQ KIT before it's patent expiration?
More Information on Dosage

FIRVANQ KIT family patents

13

United States

2

European Union

1

Australia

1

Spain

1

Canada

1

China

1

Japan

39. List of Genosyl drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10737051 VERO BIOTECH Nitrogen dioxide storage device
Oct, 2035

(12 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: NA

Dosage: GAS;INHALATION

More Information on Dosage

GENOSYL family patents

5

United States

3

Australia

3

Japan

1

Canada

1

European Union

40. List of Hetlioz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(12 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(12 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 1, 2023
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon

Dosage: CAPSULE;ORAL

How can I launch a generic of HETLIOZ before it's patent expiration?
More Information on Dosage

HETLIOZ family patents

59

United States

22

Japan

19

Australia

18

Korea, Republic of

10

Canada

10

European Union

8

Mexico

8

China

5

Israel

4

Chile

4

Spain

4

Russia

4

New Zealand

2

Brazil

2

Slovenia

2

Hungary

2

Portugal

2

Colombia

2

Croatia

2

India

2

Denmark

1

Hong Kong

41. List of Hetlioz Lq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(12 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(12 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Dec 1, 2023
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon

Dosage: SUSPENSION;ORAL

More Information on Dosage

HETLIOZ LQ family patents

59

United States

22

Japan

19

Australia

18

Korea, Republic of

10

Canada

10

European Union

8

Mexico

8

China

5

Israel

4

Chile

4

Spain

4

Russia

4

New Zealand

2

Brazil

2

Slovenia

2

Hungary

2

Portugal

2

Colombia

2

Croatia

2

India

2

Denmark

1

Hong Kong

42. List of Illuccix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027031 TELIX Kit for radiolabelling
Jul, 2035

(12 years from now)

Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Market Authorisation Date: 17 December, 2021

Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ILLUCCIX family patents

10

United States

6

Australia

6

European Union

3

Canada

2

Brazil

2

Spain

2

Russia

2

New Zealand

2

Israel

2

Mexico

2

China

2

Japan

1

Hungary

1

South Africa

1

Belgium

1

Poland

1

Portugal

1

Denmark

43. List of Imbruvica drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9795604

(Pediatric)

PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Apr, 2035

(12 years from now)

US10463668

(Pediatric)

PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Apr, 2035

(12 years from now)

US10695350

(Pediatric)

PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Apr, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
M Jan 25, 2022
New Patient Population (NPP) Aug 24, 2025
Orphan Drug Exclusivity (ODE) Aug 2, 2024
Pediatric Exclusivity (PED) Feb 24, 2026

Drugs and Companies using IBRUTINIB ingredient

Market Authorisation Date: 13 November, 2013

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of IMBRUVICA before it's patent expiration?
More Information on Dosage

44. List of Impoyz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855334 PRIMUS PHARMS Topical compositions comprising a corticosteroid
Mar, 2035

(12 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: NA

Dosage: CREAM;TOPICAL

How can I launch a generic of IMPOYZ before it's patent expiration?
More Information on Dosage

IMPOYZ family patents

6

United States

2

Korea, Republic of

2

Japan

1

Brazil

1

Ukraine

1

Australia

1

Spain

1

Canada

1

New Zealand

1

Colombia

1

Mexico

1

Russia

1

EA

1

China

1

European Union

45. List of Inlyta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Feb, 2035

(11 years from now)

Drugs and Companies using AXITINIB ingredient

Market Authorisation Date: 27 January, 2012

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's patent expiration?
More Information on Dosage

INLYTA family patents

6

United States

3

Japan

3

European Union

2

Poland

2

Spain

2

Slovenia

2

Hungary

2

Portugal

2

Singapore

1

Korea, Republic of

1

Brazil

1

Australia

1

Cyprus

1

Mexico

1

EA

1

China

1

Turkey

1

Canada

1

Taiwan, Province of China

1

Denmark

46. List of Isturisa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143680 RECORDATI RARE Pharmaceutical dosage forms
Jul, 2035

(12 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms
Oct, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2025
Orphan Drug Exclusivity (ODE) Mar 6, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: March, 2024

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage

ISTURISA family patents

4

United States

2

Japan

2

EA

2

European Union

1

Korea, Republic of

1

Australia

1

Chile

1

Poland

1

Lithuania

1

Spain

1

Israel

1

Cyprus

1

Mexico

1

Tunisia

1

Slovenia

1

IB

1

Hungary

1

Argentina

1

Portugal

1

Peru

1

Singapore

1

China

1

Croatia

1

Philippines

1

Canada

1

Taiwan, Province of China

1

Denmark

1

Ecuador

47. List of Jublia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478601 BAUSCH Applicator
Apr, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Apr 27, 2023

Drugs and Companies using EFINACONAZOLE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient

Dosage: SOLUTION;TOPICAL

How can I launch a generic of JUBLIA before it's patent expiration?
More Information on Dosage

JUBLIA family patents

2

Japan

1

China

1

Korea, Republic of

1

Australia

1

Spain

1

Portugal

1

Canada

1

Poland

1

Russia

1

Taiwan, Province of China

1

Denmark

1

United States

1

Mexico

1

European Union

48. List of Kapspargo Sprinkle drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504655 SPIL Capsule dosage form of metoprolol succinate
Jul, 2035

(12 years from now)

US9700530 SPIL Capsule dosage form of metoprolol succinate
Jul, 2035

(12 years from now)

Drugs and Companies using METOPROLOL SUCCINATE ingredient

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

KAPSPARGO SPRINKLE family patents

5

United States

1

IB

1

Brazil

1

Australia

1

Canada

1

Mexico

1

Japan

1

European Union

49. List of Kengreal drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039780 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(12 years from now)

US9700575 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(12 years from now)

US9439921 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(12 years from now)

US9295687 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(12 years from now)

Drugs and Companies using CANGRELOR ingredient

Market Authorisation Date: 22 June, 2015

Treatment: Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous infusion

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of KENGREAL before it's patent expiration?
More Information on Dosage

KENGREAL family patents

6

United States

2

Peru

1

Morocco

1

Korea, Republic of

1

Brazil

1

Chile

1

Canada

1

Colombia

1

Russia

1

Mexico

1

China

1

European Union

50. List of Kimyrsa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 12, 2024
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 12 March, 2021

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

KIMYRSA family patents

5

United States

1

Hong Kong

1

Brazil

1

Australia

1

New Zealand

1

Canada

1

Mexico

1

EA

1

China

1

Japan

1

European Union

51. List of Lenvima drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10407393 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

US11186547 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

US10259791 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 15, 2025
New Indication (I) Aug 10, 2024
M Dec 19, 2024

Drugs and Companies using LENVATINIB MESYLATE ingredient

Market Authorisation Date: 13 February, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of LENVIMA before it's patent expiration?
More Information on Dosage

LENVIMA family patents

6

United States

4

Japan

4

European Union

2

Korea, Republic of

2

Jordan

2

Singapore

2

China

1

RS

1

Brazil

1

Australia

1

Poland

1

Lithuania

1

Spain

1

Mexico

1

Slovenia

1

Hungary

1

Argentina

1

Portugal

1

Russia

1

Croatia

1

Canada

1

Taiwan, Province of China

1

Denmark

52. List of Licart drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11344520 IBSA INST BIO Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug
Feb, 2035

(12 years from now)

US11351133 IBSA INST BIO Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug
Feb, 2035

(12 years from now)

Drugs and Companies using DICLOFENAC EPOLAMINE ingredient

Market Authorisation Date: 19 December, 2018

Treatment: Method of treating acute pain due to minor strains, sprains, and contusions using a diclofenac patch containing heparin for once daily administration where heparin is not released

Dosage: SYSTEM;TOPICAL

More Information on Dosage

53. List of Lokelma drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9592253 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(12 years from now)

US10300087 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 18, 2023
M Apr 24, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of LOKELMA before it's patent expiration?
More Information on Dosage

LOKELMA family patents

4

United States

2

EA

2

China

1

Hong Kong

1

Korea, Republic of

1

Brazil

1

Australia

1

Chile

1

Malaysia

1

Israel

1

Mexico

1

Japan

1

Argentina

1

South Africa

1

Philippines

1

Canada

1

Taiwan, Province of China

1

Costa Rica

1

European Union

54. List of Lonhala Magnair Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376661 SUNOVION RESP Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element
Sep, 2035

(12 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage

LONHALA MAGNAIR KIT family patents

3

European Union

1

Spain

1

Canada

1

United States

1

China

55. List of Mavyret drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE48923 ABBVIE INC Crystal forms
May, 2035

(12 years from now)

US9321807 ABBVIE INC Crystal forms
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48923

(Pediatric)

ABBVIE INC Crystal forms
Nov, 2035

(12 years from now)

US9321807

(Pediatric)

ABBVIE INC Crystal forms
Dec, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 3, 2022
New Patient Population (NPP) Apr 30, 2022
Orphan Drug Exclusivity (ODE) Jun 10, 2028
New Dosing Schedule (D) Sep 26, 2022
M Apr 10, 2023
Pediatric Exclusivity (PED) Feb 3, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

MAVYRET family patents

4

United States

2

Australia

2

Japan

1

Canada

1

Mexico

1

China

1

European Union

56. List of Narcan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9775838 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(12 years from now)

US9468747 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(12 years from now)

US9629965 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(12 years from now)

US9561177 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(12 years from now)

US9211253 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(12 years from now)

US9480644 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(12 years from now)

US10085937 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(12 years from now)

US9707226 EMERGENT Nasal drug products and methods of their use
Mar, 2035

(12 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 November, 2015

Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of NARCAN before it's patent expiration?
More Information on Dosage

NARCAN family patents

23

United States

3

Japan

3

European Union

2

Canada

2

Israel

2

Singapore

2

Russia

2

Mexico

2

China

1

Hong Kong

1

IB

1

United Kingdom

1

Australia

1

Spain

1

Germany

57. List of Nityr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10328029 CYCLE PHARMS LTD Pharmaceutical composition
Jan, 2035

(11 years from now)

Drugs and Companies using NITISINONE ingredient

Market Authorisation Date: 26 July, 2017

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Dosage: TABLET;ORAL

More Information on Dosage

NITYR family patents

2

United Kingdom

1

Slovenia

1

RS

1

Hungary

1

Spain

1

Portugal

1

Canada

1

Poland

1

Lithuania

1

Denmark

1

United States

1

Croatia

1

European Union

58. List of Obredon drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9549907 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(12 years from now)

US10105324 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(12 years from now)

US9808431 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(12 years from now)

Drugs and Companies using GUAIFENESIN; HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 14 November, 2014

Treatment: A method of increasing the bioavailability of guaifenesin in a solution containing 54% to 66% by weight of propylene glycol and glycerol, wherein the method increases the cmax by at least 1.5 and/or increases the auc (0-inf) by at least 1.4

Dosage: SOLUTION;ORAL

More Information on Dosage

59. List of Omlonti drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10774072 SANTEN Crystal of N-substituted sulfonamide compound
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10179127 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US10765750 SANTEN Pharmaceutical composition containing pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

USRE48183 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US9415038 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US10702511 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US11197849 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

OMLONTI family patents

15

United States

12

Japan

5

European Union

4

Spain

4

China

3

Korea, Republic of

3

Mexico

3

Canada

2

Hong Kong

2

Brazil

2

Australia

2